Sunday, November 8, 2026

GBP/EUR Rises By 1% In The Last 21 Sessions

ViaNews Editorial Team

August 17, 2023

GBP/EUR Rises By 1% In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.59% for the last 21 sessions. At 12:09 EST on Thursday, 17 August, GBP/EUR (GBPEUR) is $1.17.

GBP/EUR's yearly highs and lows, it's 8.471% up from its 52-week low and 1.362% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was 0.21%, 0.01%, and 0.25%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.38% (last week), 0.25% (last month), and 0.25% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy holds steady around mid-145.00s, bulls retain control near YTD peak. According to FXStreet on Tuesday, 15 August, "The USD/JPY pair oscillates in a narrow band around mid-145.00s during the Asian session on Tuesday and consolidates its recent gains to a fresh high since November 2022. ", "This, along with the recent widening of the US-Japan rate differential, might continue to undermine the JPY and favours the USD/JPY bulls. "
  • Usd/jpy trades flat following US retail sales, still above 145.00. According to FXStreet on Tuesday, 15 August, "On the bright side, speculations of a potential Bank of Japan (BoJ) intervention to stop the currency's loss is the only hope for the Yen while the USD/JPY consolidated above the 145.00 level.", "The technical analysis of the daily chart supports a bullish view of USD/JPY in the short term. "
  • Japan Q2 GDP improves to 1.5% qoq versus 0.8% expected and 0.7% prior, usd/jpy slides below 145.50. According to FXStreet on Tuesday, 15 August, "Following the data, USD/JPY refreshed intraday low to 145.37, around 145.45 by the press time, while extending the late Monday's U-turn from the highest level since November 2022, as well as probing the five-day uptrend."
  • Usd/jpy price analysis: bulls could pause near ascending channel hurdle, around 146.00. According to FXStreet on Tuesday, 15 August, "The subsequent fall could then drag the USD/JPY pair to the 144.00 mark and then to the 143.30 horizontal support.", "This, in turn, is seen as a key factor acting as a tailwind for the USD/JPY pair amid the underlying bullish tone around the US Dollar (USD), supported by expectations that the Federal Reserve (Fed) will keep rates higher for longer."
  • Usd/jpy consolidates near mid-145.00s, just below YTD peak set on Tuesday. According to FXStreet on Wednesday, 16 August, "This might influence the USD price dynamics and provide some impetus to the USD/JPY pair. ", "The USD/JPY pair holds steady around mid-145.00s during the Asian session on Wednesday and remains well within the striking distance of its highest level since November 2022 touched the previous day."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com
GBP/EUR Rises By 1% In The Last 21 Sessions | Via News